✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Metoclopramide Hydrochloride is a drug marketed by Bedford, Fresenius Kabi Usa, Hospira, Lyphomed, Norbrook, Smith And Nephew, Teva Pharms Usa, Actavis Mid Atlantic, Ani Pharms, Chartwell Molecular, Morton Grove, Paco, Pharm Assoc, Roxane, Teva, Vistapharm, Wockhardt Bio Ag, Novel Labs Inc, Chartwell Rx, Clonmel, Halsey, Impax Labs Inc, Interpharm, Ipca Labs Ltd, Mutual Pharm, Northstar Hlthcare, Par Pharm, Sandoz, Schering, Strides Pharma, Sun Pharm Industries, Superpharm, Usl Pharma, and Watson Labs. and is included in fifty-three NDAs.
The generic ingredient in METOCLOPRAMIDE HYDROCHLORIDE is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.
A generic version of METOCLOPRAMIDE HYDROCHLORIDE was approved as metoclopramide hydrochloride by TEVA on July 29th, 1985.
Summary for METOCLOPRAMIDE HYDROCHLORIDE
Recent Clinical Trials for METOCLOPRAMIDE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|Tanta University||Phase 2|
|Instituto Mexicano del Seguro Social||Phase 4|